D3 Bio closed a $108 million Series B to finance the global phase III development of its oral KRAS G12C inhibitor elisrasib (D3S‑001). The Shanghai‑based company, led by an AstraZeneca veteran, intends to use proceeds to support registrational trials and global expansion plans for the candidate. KRAS G12C remains a high‑value oncology target; D3’s financing joins a wave of sizable rounds aimed at accelerating late‑stage programs for targeted oncology assets. Investors signaled confidence in D3’s preclinical and early clinical performance and the team’s ability to execute a global registrational strategy. The raise positions D3 to compete in a crowded KRAS inhibitor landscape and underscores sustained investor capital availability for late‑stage oncology small molecules with clear regulatory pathways.